After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
50m
Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback